Literature DB >> 34686522

Ontogeny of Scaling Factors for Pediatric Physiology-Based Pharmacokinetic Modeling and Simulation: Microsomal Protein Per Gram of Liver.

J Steven Leeder1, Jean C Dinh2, Andrea Gaedigk2, Vincent S Staggs2, Bhagwat Prasad2, Robin E Pearce2.   

Abstract

Microsomal protein per gram of liver (MPPGL) is an important scaling factor for bottom-up physiology-based pharmacokinetic modeling and simulation, but data in pediatrics are limited. Therefore, MPPGL was determined in 160 liver samples from pediatric (n = 129) and adult (n = 31) donors obtained from four sources: the University of Maryland Brain and Tissue Bank (UMBTB), tissue retrieval services at the University of Minnesota and University of Pittsburgh, and Sekisui-Xenotech. Tissues were homogenized and subjected to differential centrifugation to prepare microsomes, and cytochrome c reductase activities in tissue homogenates and microsomes were used to estimate cytochrome P450 reductase (POR) activity as a marker of microsomal recovery; microsomal POR content was also assessed by quantitative proteomics. MPPGL values varied 5- to 10-fold within various age groups/developmental stages, and tissue source was identified as a contributing factor. Using a "trimmed" dataset comprised of samples ranging from 3 to 18 years of age common to the four sources, POR protein abundance and activity in microsomes and POR activity in homogenates was lower in UMBTB samples (autopsy) compared with other sources (perfused/flash-frozen). Regression analyses revealed that the UMBTB samples were driving an apparent age effect as no effect of age on log-transformed MPPGL values was observed when the UMBTB samples were excluded. We conclude that a mean±SD MPPGL value of 30.4±1.7 mg/g is representative between one month postnatal age and early adulthood. Potential source effects should be considered for studies involving tissue samples from multiple sources with different procurement and processing procedures. SIGNIFICANCE STATEMENT: Microsomal protein per gram of liver (MPPGL) is an important scaling factor for bottom up PBPK modeling and simulation, but data in pediatrics are limited. Although MPPGL varies 5- to 10-fold at a given developmental stage, a value of 30.4 ± 1.7 mg/g (mean ± SD) is representative between one month postnatal age and early adulthood. However, when tissue samples are obtained from multiple sources, different procurement and processing procedures may influence the results and should be taken into consideration.
Copyright © 2021 by The American Society for Pharmacology and Experimental Therapeutics.

Entities:  

Mesh:

Substances:

Year:  2021        PMID: 34686522      PMCID: PMC8969199          DOI: 10.1124/dmd.121.000623

Source DB:  PubMed          Journal:  Drug Metab Dispos        ISSN: 0090-9556            Impact factor:   3.922


  25 in total

1.  Changes in liver volume from birth to adulthood: a meta-analysis.

Authors:  Trevor N Johnson; Geoffrey T Tucker; M Stuart Tanner; Amin Rostami-Hodjegan
Journal:  Liver Transpl       Date:  2005-12       Impact factor: 5.799

Review 2.  Mechanism-based concepts of size and maturity in pharmacokinetics.

Authors:  B J Anderson; N H G Holford
Journal:  Annu Rev Pharmacol Toxicol       Date:  2008       Impact factor: 13.820

3.  Parameterization of Microsomal and Cytosolic Scaling Factors: Methodological and Biological Considerations for Scalar Derivation and Validation.

Authors:  Michael J Doerksen; Robert S Jones; Michael W H Coughtrie; Abby C Collier
Journal:  Eur J Drug Metab Pharmacokinet       Date:  2020-12-19       Impact factor: 2.441

Review 4.  Pharmacometric Modeling and Simulation Is Essential to Pediatric Clinical Pharmacology.

Authors:  Michael Neely; David Bayard; Amit Desai; Laura Kovanda; Andrea Edginton
Journal:  J Clin Pharmacol       Date:  2018-10       Impact factor: 3.126

5.  Partial purification of cytochromes P-450 and P-448 from rat liver microsomes.

Authors:  A Y Lu; W Levin
Journal:  Biochem Biophys Res Commun       Date:  1972-02-16       Impact factor: 3.575

6.  Determination of a human hepatic microsomal scaling factor for predicting in vivo drug clearance.

Authors:  Nancy Hakooz; Kiyomi Ito; Helen Rawden; Helen Gill; Lynn Lemmers; Alan R Boobis; Robert J Edwards; David J Carlile; Brian G Lake; J Brian Houston
Journal:  Pharm Res       Date:  2006-02-28       Impact factor: 4.200

7.  The Impact of Age and Genetics on Naltrexone Biotransformation.

Authors:  Stephani L Stancil; Whitney Nolte; Robin E Pearce; Vincent S Staggs; J Steven Leeder
Journal:  Drug Metab Dispos       Date:  2021-11-02       Impact factor: 3.579

8.  Scaling Drug Clearance from Adults to the Young Children for Drugs Undergoing Hepatic Metabolism: A Simulation Study to Search for the Simplest Scaling Method.

Authors:  E A M Calvier; E H J Krekels; T N Johnson; A Rostami-Hodjegan; D Tibboel; Catherijne A J Knibbe
Journal:  AAPS J       Date:  2019-03-08       Impact factor: 4.009

9.  Hepatic Abundance and Activity of Androgen- and Drug-Metabolizing Enzyme UGT2B17 Are Associated with Genotype, Age, and Sex.

Authors:  Deepak Kumar Bhatt; Abdul Basit; Haeyoung Zhang; Andrea Gaedigk; Seung-Been Lee; Katrina G Claw; Aanchal Mehrotra; Amarjit Singh Chaudhry; Robin E Pearce; Roger Gaedigk; Ulrich Broeckel; Timothy A Thornton; Deborah A Nickerson; Erin G Schuetz; John K Amory; J Steven Leeder; Bhagwat Prasad
Journal:  Drug Metab Dispos       Date:  2018-03-30       Impact factor: 3.922

10.  Allometric Scaling of Clearance in Paediatric Patients: When Does the Magic of 0.75 Fade?

Authors:  Elisa A M Calvier; Elke H J Krekels; Pyry A J Välitalo; Amin Rostami-Hodjegan; Dick Tibboel; Meindert Danhof; Catherijne A J Knibbe
Journal:  Clin Pharmacokinet       Date:  2017-03       Impact factor: 6.447

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.